Novo Nordisk
Danish pharmaceutical company pioneering GLP-1 weight loss drugs, with 85% gross margins and 69% ROIC, trading at 28x P/E versus Eli Lilly at 75x
Novo Nordisk
Overview
Novo Nordisk is a Danish pharmaceutical company that has become the global pioneer in GLP-1 (glucagon-like peptide-1) weight loss drugs. Founded in 1923, the company has transformed from a diabetes-focused insulin manufacturer into the leader of a potentially $100-350 billion obesity treatment market. Despite a 45% share price drawdown in 2024, Fundsmith maintains its position, viewing it as one of the most compelling quality businesses in their portfolio.
Investment Highlights (2024-2025)
Financial Metrics
| Metric | Novo Nordisk | Fundsmith Portfolio Avg | Eli Lilly (Competitor) |
|---|---|---|---|
| Revenue Growth | 25% | — | ~20% |
| Gross Margin | 85% | 64% | ~75% |
| Operating Margin | 44% | 30% | ~35% |
| Return on Capital | 69% | 30% | ~25% |
| P/E Ratio | 28x | — | 75x |
| Free Cash Flow Yield | 27% | — | ~3% |
Competitive Advantages
1. Manufacturing Efficiency
"Making these drugs is non-trivial – we're talking about 31 amino acids in sequence."
Novo Nordisk purchased three manufacturing plants for $10 billion to scale production capacity.
2. Patents — Broad intellectual property protection
3. Capacity — Significant capital invested in manufacturing scale
4. Additional Treatment Labels — Expanding beyond weight loss to:
- Cardiovascular function
- Kidney function
- Liver function
- Alzheimer's
- Autoimmune conditions
- Various forms of addiction
Julian Robbins quoted an industry executive: "I think they've invented the elixir of life."
Market Opportunity
The Obesity Market
- Current size: $31.6 billion
- Estimated opportunity: $100-350 billion
- Companies working on weight loss drugs: At least 400
Market Share Dynamics
Novo Nordisk currently commands approximately two-thirds of the GLP-1 market. This concentration won't persist as competition intensifies, but the market itself will likely be 3-10x larger.
Product Evolution
Current injectables will evolve to include oral options. The category will shift from "weight loss" to "weight management" drugs taken daily like statins or aspirin.
Impact on Consumer Industries
Alcohol Companies
Fundsmith sold Diageo citing GLP-1 drugs' impact:
- Data from 150,000 US households shows alcoholic drinks are among the first consumption areas reduced
- Generation Z is the "sober curious generation" with significantly lower alcohol consumption
Consumer Goods
The structural disruption extends beyond alcohol:
- Marijuana legalization (24 states recreationally, 39 medically) further impacts alcohol consumption
- Shift in consumer behavior toward health and wellness
Fundsmith's Position
Fundsmith bought Novo Nordisk approximately six years ago before weight loss was mentioned, based on their drug discovery process. Despite the 45% drawdown, they maintain their position because:
- The competitive moat remains significant
- Manufacturing efficiency is difficult to replicate
- The market opportunity is enormous
- Valuation (28x P/E) is reasonable versus Eli Lilly (75x)
Related Concepts
- moat — Wide economic moat through manufacturing, patents, and capacity
- quality-investing — Exceptional quality metrics (85% margins, 69% ROIC)
- competitive-advantage — Manufacturing complexity creates barriers to entry
Related People
- terry-smith — Fundsmith CIO who maintains the position despite controversy
- julian-robbins — Fundsmith Head of Research
Further Reading
- Fundsmith 2025 AGM Transcript — Extensive discussion of Novo Nordisk
- Novo Nordisk Official Website